{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:13Z","timestamp":1707524953869},"reference-count":90,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,24]]},"DOI":"10.7759\/cureus.36642","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T17:54:33Z","timestamp":1679680473000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes of Autologous Hematopoietic Stem Cell Transplant (HSCT) for Multiple Myeloma: While New Horizons Emerge, It Is Still Only a Silver Lining for Resource-Constrained Settings"],"prefix":"10.7759","author":[{"given":"Saquib  Z","family":"Banday","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Guru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maniza","family":"Ayub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed N","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaqib Z","family":"Banday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohmad H","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahila","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleem","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gull M","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheikh A","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125232","article-title":"One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the worldwide network for blood and marrow transplantation (WBMT)","volume":"134","author":"Niederwieser D","year":"2019","unstructured":"Niederwieser D, Baldomero H, Atsuta Y, et al.. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the worldwide network for blood and marrow transplantation (WBMT). Blood. 2019, 134:2035. 10.1182\/blood-2019-125232","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.245688","article-title":"History of hematopoietic cell transplantation: challenges and progress","volume":"105","author":"Granot N","year":"2020","unstructured":"Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020, 105:2716-29. 10.3324\/haematol.2019.245688","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0554-9","article-title":"Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015","volume":"54","author":"Iida M","year":"2019","unstructured":"Iida M, Kodera Y, Dodds A, et al.. Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015. Bone Marrow Transplant. 2019, 54:1973-86. 10.1038\/s41409-019-0554-9","journal-title":"Bone Marrow Transplant"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00198-2","article-title":"A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017","volume":"10","author":"Keykhaei M","year":"2021","unstructured":"Keykhaei M, Masinaei M, Mohammadi E, et al.. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017. Exp Hematol Oncol. 2021, 10:11. 10.1186\/s40164-021-00198-2","journal-title":"Exp Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar SV","year":"2016","unstructured":"Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016, 91:719-34. 10.1002\/ajh.24402","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040863","article-title":"Role of stem cell transplantation in multiple myeloma","volume":"13","author":"Devarakonda S","year":"2021","unstructured":"Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. Cancers (Basel). 2021, 13:10.3390\/cancers13040863","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma","volume":"9","author":"Mahajan S","year":"2018","unstructured":"Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. Ther Adv Hematol. 2018, 9:123-33. 10.1177\/2040620718761776","journal-title":"Ther Adv Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi PN","year":"2020","unstructured":"Munshi PN, Vesole D, Jurczyszyn A, et al.. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020, 126:5077-87. 10.1002\/cncr.33171","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra A","year":"2017","unstructured":"Mahindra A, Hari P, Fraser R, et al.. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017, 52:1616-22. 10.1038\/bmt.2017.198","journal-title":"Bone Marrow Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061640","article-title":"Feasibility of outpatient stem cell transplantation in multiple myeloma and risk factors predictive of hospital admission","volume":"11","author":"Larsen K","year":"2022","unstructured":"Larsen K, Spencer H, Mohan M, et al.. Feasibility of outpatient stem cell transplantation in multiple myeloma and risk factors predictive of hospital admission. J Clin Med. 2022, 11:10.3390\/jcm11061640","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.08.018","article-title":"The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study","volume":"26","author":"Cowan AJ","year":"2020","unstructured":"Cowan AJ, Baldomero H, Atsuta Y, et al.. The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biol Blood Marrow Transplant. 2020, 26:2372-7. 10.1016\/j.bbmt.2020.08.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza A","year":"2020","unstructured":"D'Souza A, Fretham C, Lee SJ, et al.. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020, 26:e177-82. 10.1016\/j.bbmt.2020.04.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0826-4","article-title":"The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus","volume":"55","author":"Passweg JR","year":"2020","unstructured":"Passweg JR, Baldomero H, Chabannon C, et al.. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. Bone Marrow Transplant. 2020, 55:1604-13. 10.1038\/s41409-020-0826-4","journal-title":"Bone Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01111-y","article-title":"Stem cell transplantation in multiple myeloma: very much alive and kicking","volume":"35","author":"Yanamandra U","year":"2019","unstructured":"Yanamandra U, Malhotra P. Stem cell transplantation in multiple myeloma: very much alive and kicking. Indian J Hematol Blood Transfus. 2019, 35:205-7. 10.1007\/s12288-019-01111-y","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0843-7","article-title":"Cost of treatment of multiple myeloma in a public sector tertiary care hospital of North India","volume":"34","author":"Kaur G","year":"2018","unstructured":"Kaur G, Prinja S, Malhotra P, et al.. Cost of treatment of multiple myeloma in a public sector tertiary care hospital of North India. Indian J Hematol Blood Transfus. 2018, 34:25-31. 10.1007\/s12288-017-0843-7","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0776-1","article-title":"Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India","volume":"33","author":"Prinja S","year":"2017","unstructured":"Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S. Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus. 2017, 33:31-40. 10.1007\/s12288-017-0776-1","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096149","article-title":"Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers","volume":"99","author":"Mohty M","year":"2014","unstructured":"Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014, 99:408-16. 10.3324\/haematol.2013.096149","journal-title":"Haematologica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies","volume":"16","author":"Parrondo RD","year":"2020","unstructured":"Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020, 16:56-66. 10.1200\/JOP.19.00335","journal-title":"JCO Oncol Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1309\/A9R91ERLU1XH5311","article-title":"Extended storage of liquid-preserved stem cells at 4\u00b0c results in good engraftment in patients of multiple myeloma undergoing autologous stem cell transplantation","volume":"36","author":"Thakral B","year":"2005","unstructured":"Thakral B, Saluja K, Sharma RR, et al.. Extended storage of liquid-preserved stem cells at 4\u00b0c results in good engraftment in patients of multiple myeloma undergoing autologous stem cell transplantation. Lab Med. 2005, 36:650-1. 10.1309\/A9R91ERLU1XH5311","journal-title":"Lab Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party","volume":"103","author":"Auner HW","year":"2018","unstructured":"Auner HW, Iacobelli S, Sbianchi G, et al.. Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018, 103:514-21. 10.3324\/haematol.2017.181339","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01795.x","article-title":"Effect of time to infusion of autologous stem cells (24 vs. 48\u00a0h) after high-dose melphalan in patients with multiple myeloma","volume":"89","author":"Talamo G","year":"2012","unstructured":"Talamo G, Rakszawski KL, Rybka WB, Dolloff NG, Malysz J, Berno T, Zangari M. Effect of time to infusion of autologous stem cells (24 vs. 48\u00a0h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol. 2012, 89:145-50. 10.1111\/j.1600-0609.2012.01795.x","journal-title":"Eur J Haematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5790.5790","article-title":"G-CSF starting day +1 after autologous transplant is safer than day +5 or day +7 in patients with multiple myeloma","volume":"128","author":"Cottini F","year":"2016","unstructured":"Cottini F, Sborov D, Cho YK, et al.. G-CSF starting day +1 after autologous transplant is safer than day +5 or day +7 in patients with multiple myeloma. Blood. 2016, 128:5790. 10.1182\/blood.V128.22.5790.5790","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562902","article-title":"Posaconazole: use in the prophylaxis and treatment of fungal infections","volume":"36","author":"Clark NM","year":"2015","unstructured":"Clark NM, Grim SA, Lynch JP 3rd. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respir Crit Care Med. 2015, 36:767-85. 10.1055\/s-0035-1562902","journal-title":"Semin Respir Crit Care Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1810-4","article-title":"Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation","volume":"102","author":"Kawamura K","year":"2015","unstructured":"Kawamura K, Hayakawa J, Akahoshi Y, et al.. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015, 102:230-7. 10.1007\/s12185-015-1810-4","journal-title":"Int J Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703389","article-title":"Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation","volume":"29","author":"Wolff SN","year":"2002","unstructured":"Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002, 29:545-52. 10.1038\/sj.bmt.1703389","journal-title":"Bone Marrow Transplant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14190","article-title":"Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients","volume":"175","author":"Teltschik HM","year":"2016","unstructured":"Teltschik HM, Heinzelmann F, Gruhn B, et al.. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 2016, 175:115-22. 10.1111\/bjh.14190","journal-title":"Br J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1543874","article-title":"A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents","volume":"60","author":"Su B","year":"2019","unstructured":"Su B, Zhu X, Jiang Y, et al.. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma. 2019, 60:1381-8. 10.1080\/10428194.2018.1543874","journal-title":"Leuk Lymphoma"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.04.007","article-title":"Analysis of clinical factors and outcomes associated with nonuse of collected peripheral blood stem cells for autologous stem cell transplants in transplant-eligible patients with multiple myeloma","volume":"24","author":"Kansagra A","year":"2018","unstructured":"Kansagra A, Gonsalves WI, Gertz MA, et al.. Analysis of clinical factors and outcomes associated with nonuse of collected peripheral blood stem cells for autologous stem cell transplants in transplant-eligible patients with multiple myeloma. Biol Blood Marrow Transplant. 2018, 24:2127-32. 10.1016\/j.bbmt.2018.04.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta JJ","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, et al.. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017, 35:2900-10. 10.1200\/JCO.2016.69.2517","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis","volume":"4","author":"Dhakal B","year":"2018","unstructured":"Dhakal B, Szabo A, Chhabra S, et al.. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:343-50. 10.1001\/jamaoncol.2017.4600","journal-title":"JAMA Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves WI","year":"2019","unstructured":"Gonsalves WI, Buadi FK, Ailawadhi S, et al.. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019, 54:353-67. 10.1038\/s41409-018-0264-8","journal-title":"Bone Marrow Transplant"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca R","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, et al.. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020, 20:1087. 10.1186\/s12885-020-07503-y","journal-title":"BMC Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1768383","article-title":"Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects","volume":"61","author":"Jansen L","year":"2020","unstructured":"Jansen L, Merz M, Engelhardt M, et al.. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. Leuk Lymphoma. 2020, 61:2365-74. 10.1080\/10428194.2020.1768383","journal-title":"Leuk Lymphoma"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1135434","article-title":"Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China","volume":"57","author":"Lu J","year":"2016","unstructured":"Lu J, Hou J, Liu KY, et al.. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma. 2016, 57:1534-8. 10.3109\/10428194.2015.1135434","journal-title":"Leuk Lymphoma"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0876-y","article-title":"Autologous stem cell transplantation for multiple myeloma: single centre experience from north India","volume":"34","author":"Malhotra P","year":"2018","unstructured":"Malhotra P, Yanamandra U, Khadwal A, et al.. Autologous stem cell transplantation for multiple myeloma: single centre experience from north India. Indian J Hematol Blood Transfus. 2018, 34:261-7. 10.1007\/s12288-017-0876-y","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3370-1","article-title":"Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma","volume":"97","author":"Aggarwal M","year":"2018","unstructured":"Aggarwal M, Agrawal N, Yadav N, et al.. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol. 2018, 97:1869-77. 10.1007\/s00277-018-3370-1","journal-title":"Ann Hematol"},{"key":"ref39","unstructured":"Government of India, Press Information Bureau. Rangarajan Report on Poverty. (2014). Accessed. 15th October 2022: https:\/\/www.pib.gov.in\/newsite\/printrelease.aspx?relid=108291."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1743504","article-title":"Case for more autologous transplants in myeloma in resource-constrained settings","volume":"43","author":"Singh S","year":"2022","unstructured":"Singh S, Sharma R. Case for more autologous transplants in myeloma in resource-constrained settings. Indian J Med Paediatr Oncol. 2022, 43:311-3. 10.1055\/s-0042-1743504","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00645-1","article-title":"Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update","volume":"12","author":"Bazarbachi AH","year":"2022","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022, 12:47. 10.1038\/s41408-022-00645-1","journal-title":"Blood Cancer J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar S","year":"2007","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al.. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007, 21:2035-42. 10.1038\/sj.leu.2404801","journal-title":"Leukemia"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405035","article-title":"Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients","volume":"22","author":"Mazumder A","year":"2008","unstructured":"Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008, 22:1280-1; author reply 1281-2. 10.1038\/sj.leu.2405035","journal-title":"Leukemia"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.071456","article-title":"Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial","volume":"98","author":"Russell N","year":"2013","unstructured":"Russell N, Douglas K, Ho AD, et al.. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica. 2013, 98:172-8. 10.3324\/haematol.2012.071456","journal-title":"Haematologica"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt S","year":"2009","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL, et al.. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009, 23:1904-12. 10.1038\/leu.2009.127","journal-title":"Leukemia"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.08.005","article-title":"Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation","volume":"19","author":"Lanza F","year":"2013","unstructured":"Lanza F, Campioni DC, Hellmann A, et al.. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2013, 19:1670-6. 10.1016\/j.bbmt.2013.08.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1360","article-title":"Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy","volume":"18","author":"Siena S","year":"2000","unstructured":"Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000, 18:1360-77. 10.1200\/JCO.2000.18.6.1360","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2001-173","article-title":"CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"50","author":"Alada\u011f Karakulak E","year":"2020","unstructured":"Alada\u011f Karakulak E, Demiro\u011flu H, B\u00fcy\u00fcka\u015fik Y, et al.. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk J Med Sci. 2020, 50:1851-6. 10.3906\/sag-2001-173","journal-title":"Turk J Med Sci"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter P","year":"2010","unstructured":"Wuchter P, Ran D, Bruckner T, et al.. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010, 16:490-9. 10.1016\/j.bbmt.2009.11.012","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2004.13.598s","article-title":"What is the optimum number of CD34 + peripheral blood stem cells for an autologous transplant?","volume":"13","author":"Jillella AP","year":"2004","unstructured":"Jillella AP, Ustun C. What is the optimum number of CD34 + peripheral blood stem cells for an autologous transplant?. Stem Cells Dev. 2004, 13:598-606. 10.1089\/scd.2004.13.598s","journal-title":"Stem Cells Dev"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26422","article-title":"Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma","volume":"118","author":"Kumar SK","year":"2012","unstructured":"Kumar SK, Lacy MQ, Dispenzieri A, et al.. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer. 2012, 118:1585-92. 10.1002\/cncr.26422","journal-title":"Cancer"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.751528","article-title":"Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma","volume":"54","author":"Dunavin NC","year":"2013","unstructured":"Dunavin NC, Wei L, Elder P, et al.. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma. 2013, 54:1658-64. 10.3109\/10428194.2012.751528","journal-title":"Leuk Lymphoma"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.12.031","article-title":"Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: single-center experience of 18 years","volume":"48","author":"Remenyi P","year":"2016","unstructured":"Remenyi P, Varga G, Mikala G, et al.. Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: single-center experience of 18 years. Transplant Proc. 2016, 48:177-84. 10.1016\/j.transproceed.2015.12.031","journal-title":"Transplant Proc"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.04.020","article-title":"Multiple myeloma: impact of time to transplant on the outcome","volume":"22","author":"Kumar L","year":"2022","unstructured":"Kumar L, Hussain MM, Chethan R, et al.. Multiple myeloma: impact of time to transplant on the outcome. Clin Lymphoma Myeloma Leuk. 2022, 22:e826-35. 10.1016\/j.clml.2022.04.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie BG","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, et al.. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017, 389:519-27. 10.1016\/S0140-6736(16)31594-X","journal-title":"Lancet"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal M","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et al.. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017, 376:1311-20. 10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt H","year":"2018","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK, et al.. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia. 2018, 32:383-90. 10.1038\/leu.2017.211","journal-title":"Leukemia"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot A","year":"2020","unstructured":"Perrot A, Lauwers-Cances V, Cazaubiel T, et al.. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020, 136:39. 10.1182\/blood-2020-134538","journal-title":"Blood"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo M","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, et al.. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020, 7:456-68. 10.1016\/S2352-3026(20)30099-5","journal-title":"Lancet Haematol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.04.004","article-title":"Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study","volume":"21","author":"Sorror ML","year":"2015","unstructured":"Sorror ML, Logan BR, Zhu X, et al.. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015, 21:1479-87. 10.1016\/j.bbmt.2015.04.004","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref61","article-title":"Autologous bone marrow\/stem cell transplantation: initial experience at a north Indian referral centre","author":"Gupta S","year":"2000","unstructured":"Gupta S, Kumar L, Raju GM, et al.. Autologous bone marrow\/stem cell transplantation: initial experience at a north Indian referral centre. Natl Med J India. 2000, 61-6.","journal-title":"Natl Med J India"},{"key":"ref62","article-title":"High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma","author":"Kumar L","year":"2003","unstructured":"Kumar L, Raju GK, Ganessan K, et al.. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Natl Med J India. 2003, 16-21.","journal-title":"Natl Med J India"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.e17003","article-title":"Outcomes of autologous stem cell transplant (ASCT) in multiple myeloma from a tertiary cancer center in India","volume":"30","author":"Bagal BP","year":"2012","unstructured":"Bagal BP, Khattry N, Dongre A, et al.. Outcomes of autologous stem cell transplant (ASCT) in multiple myeloma from a tertiary cancer center in India. J Clin Oncol. 2012, 30:17003. 10.1200\/jco.2012.30.15_suppl.e17003","journal-title":"J Clin Oncol"},{"key":"ref64","article-title":"Auto-SCT for myeloma patients in non-HEPA filtered room: initial experience of a tertiary care center","volume":"54 Suppl 1","author":"Dolai TK","year":"2013","unstructured":"Dolai TK, Kumar M, Mandal PK, et al.. Auto-SCT for myeloma patients in non-HEPA filtered room: initial experience of a tertiary care center. Leuk Lymphoma. 2013, 54 Suppl 1:26.","journal-title":"Leuk Lymphoma"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.09.001","article-title":"High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells","volume":"14","author":"Kayal S","year":"2014","unstructured":"Kayal S, Sharma A, Iqbal S, Tejomurtula T, Cyriac SL, Raina V. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clin Lymphoma Myeloma Leuk. 2014, 14:140-7. 10.1016\/j.clml.2013.09.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.257","article-title":"Complete response after autologous stem cell transplant in multiple myeloma","volume":"3","author":"Kumar L","year":"2014","unstructured":"Kumar L, Iqbal N, Mookerjee A, et al.. Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med. 2014, 3:939-46. 10.1002\/cam4.257","journal-title":"Cancer Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2015-0015","article-title":"Autologous hematopoietic stem cell transplantation-10 years of data from a developing country","volume":"4","author":"Ali N","year":"2015","unstructured":"Ali N, Adil SN, Shaikh MU. Autologous hematopoietic stem cell transplantation-10 years of data from a developing country. Stem Cells Transl Med. 2015, 4:873-7. 10.5966\/sctm.2015-0015","journal-title":"Stem Cells Transl Med"},{"key":"ref68","article-title":"Autologous stem cell transplantation for multiple myeloma: Long-term results","author":"Kumar L","year":"2016","unstructured":"Kumar L, Boya RR, Pai R, et al.. Autologous stem cell transplantation for multiple myeloma: Long-term results. Natl Med J India. 2016, 192-9.","journal-title":"Natl Med J India"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017GS101643","article-title":"The journey of stem cell transplantation in Bangladesh: a hike to the state of the art with collaboration between DMCH and MGH","volume":"1","author":"Akter M","year":"2017","unstructured":"Akter M, Khan MA, Yeh AC, et al.. The journey of stem cell transplantation in Bangladesh: a hike to the state of the art with collaboration between DMCH and MGH. Blood Adv. 2017, 1:62-4. 10.1182\/bloodadvances.2017GS101643","journal-title":"Blood Adv"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.277","article-title":"Assessment of quality of life in myeloma patients post autologous stem cell transplant- a single centre experience in south India","volume":"17","author":"Damodar S","year":"2017","unstructured":"Damodar S, Karanth S, Nataraj KS, et al.. Assessment of quality of life in myeloma patients post autologous stem cell transplant- a single centre experience in south India. Clin Lymphoma Myeloma Leuk. 2017, 17:153-4. 10.1016\/j.clml.2017.03.277","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.228","article-title":"High dose chemotherapy with autologous stem cell transplantation for multiple myeloma: outcomes at tata memorial centre","volume":"17","author":"Gokarn A","year":"2017","unstructured":"Gokarn A, Bonda A, Mathew L, et al.. High dose chemotherapy with autologous stem cell transplantation for multiple myeloma: outcomes at tata memorial centre. Clin Lymphoma Myeloma Leuk. 2017, 17:126. 10.1016\/j.clml.2017.03.228","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017GS101637","article-title":"Where there\u2019s a will, there\u2019s a way: establishing hematopoietic stem cell transplantation in Myanmar","volume":"1","author":"Gyi AA","year":"2017","unstructured":"Gyi AA, Mra R, Nyein HL, et al.. Where there\u2019s a will, there\u2019s a way: establishing hematopoietic stem cell transplantation in Myanmar. Blood Adv. 2017, 1:65-9. 10.1182\/bloodadvances.2017GS101637","journal-title":"Blood Adv"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018GS110686","article-title":"Working together: establishment of the first national hematopoietic stem cell transplantation (HSCT) center in Sri Lanka","volume":"2","author":"Abeysinghe P","year":"2018","unstructured":"Abeysinghe P, Morawaka L, Gunasekara S, et al.. Working together: establishment of the first national hematopoietic stem cell transplantation (HSCT) center in Sri Lanka. Blood Adv. 2018, 2:46-9. 10.1182\/bloodadvances.2018GS110686","journal-title":"Blood Adv"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_656_17","article-title":"Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: an institutional audit","volume":"55","author":"Khattry N","year":"2018","unstructured":"Khattry N, Laskar S, Sengar M, et al.. Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: an institutional audit. Indian J Cancer. 2018, 55:9-15. 10.4103\/ijc.IJC_656_17","journal-title":"Indian J Cancer"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_187_18","article-title":"Autologous stem cell transplantation in elderly myeloma patients (>65 years): single institutional experience","volume":"55","author":"Jena RK","year":"2018","unstructured":"Jena RK, Sethy S, Panigrahi A, Panda T. Autologous stem cell transplantation in elderly myeloma patients (>65 years): single institutional experience. Indian J Cancer. 2018, 55:307-9. 10.4103\/ijc.IJC_187_18","journal-title":"Indian J Cancer"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-018-0951-z","article-title":"Autologous hematopoietic stem cell transplantation for multiple myeloma\u00a0in India","volume":"34","author":"Naithani R","year":"2018","unstructured":"Naithani R, Dayal N, Rai R, Pathak S, Singh M. Autologous hematopoietic stem cell transplantation for multiple myeloma\u00a0in India. Indian J Hematol Blood Transfus. 2018, 34:564-5. 10.1007\/s12288-018-0951-z","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref77","article-title":"Multiple myeloma- real world experience of transplantation in multiple myeloma from a tertiary care center in North India","volume":"34","author":"Yanamandra U","year":"2018","unstructured":"Yanamandra U, Yadav S, Das SR, et al.. Multiple myeloma- real world experience of transplantation in multiple myeloma from a tertiary care center in North India. Indian J Hematol Blood Transfus. 2018, 34:61.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref78","article-title":"Autologous stem cell transplant program in 2016\u2012country report from Bangladesh","volume":"3","author":"Akter M","year":"2020","unstructured":"Akter M, Khan MA, Dey BR. Autologous stem cell transplant program in 2016\u2012country report from Bangladesh. BCT. 2020, 3:1-5.","journal-title":"BCT"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(19)30299-1","article-title":"Outcome of autologous stem cell transplantation in multiple myeloma, in the era of novel agents: a single-centre experience","volume":"85","author":"Bafna V","year":"2019","unstructured":"Bafna V, Damodar S, Bendi C. Outcome of autologous stem cell transplantation in multiple myeloma, in the era of novel agents: a single-centre experience. Leuk Res. 2019, 85:41. 10.1016\/S0145-2126(19)30299-1","journal-title":"Leuk Res"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-018-0989-y","article-title":"Clinical outcomes in multiple myeloma post-autologous transplantation-a single centre experience","volume":"35","author":"Kulkarni U","year":"2019","unstructured":"Kulkarni U, Devasia AJ, Korula A, et al.. Clinical outcomes in multiple myeloma post-autologous transplantation-a single centre experience. Indian J Hematol Blood Transfus. 2019, 35:215-22. 10.1007\/s12288-018-0989-y","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_1593_18","article-title":"High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome","volume":"149","author":"Kumar L","year":"2019","unstructured":"Kumar L, Ramavath D, Kataria B, et al.. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome. Indian J Med Res. 2019, 149:730-9. 10.4103\/ijmr.IJMR_1593_18","journal-title":"Indian J Med Res"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.312","article-title":"Autologous stem cell transplantation in multiple myeloma: experience of a single center from Eastern India","volume":"19","author":"Kumar J","year":"2019","unstructured":"Kumar J, Nair R, Radhakrishnan V, et al.. Autologous stem cell transplantation in multiple myeloma: experience of a single center from Eastern India. Clin Lymphoma Myeloma Leuk. 2019, 19:326. 10.1016\/j.clml.2019.07.312","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106167","article-title":"Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: lesson from a tertiary cancer centre in rural India","volume":"83","author":"Nair CK","year":"2019","unstructured":"Nair CK, Selvaraj K, Raghavan V, et al.. Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: lesson from a tertiary cancer centre in rural India. Leuk Res. 2019, 83:106167. 10.1016\/j.leukres.2019.106167","journal-title":"Leuk Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.02.011","article-title":"Hematopoietic stem cell transplantation in Nepal: international partnership, implementation steps, and clinical outcomes","volume":"28","author":"Poudyal BS","year":"2022","unstructured":"Poudyal BS, Tuladhar S, Neupane S, et al.. Hematopoietic stem cell transplantation in Nepal: international partnership, implementation steps, and clinical outcomes. Transplant Cell Ther. 2022, 28:268-75. 10.1016\/j.jtct.2022.02.011","journal-title":"Transplant Cell Ther"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-022-00123-6","article-title":"The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis","volume":"34","author":"Revannasiddaiah S","year":"2022","unstructured":"Revannasiddaiah S, Nagaraju PR, Palassery R, et al.. The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis. J Egypt Natl Canc Inst. 2022, 34:21. 10.1186\/s43046-022-00123-6","journal-title":"J Egypt Natl Canc Inst"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-021-01485-y","article-title":"A multicenter study of clinical presentations and outcomes of multiple myeloma in Pakistan: the real-world analysis in a resource-constrained country","volume":"38","author":"Saeed N","year":"2022","unstructured":"Saeed N, Ahmad U, Moosajee M, et al.. A multicenter study of clinical presentations and outcomes of multiple myeloma in Pakistan: the real-world analysis in a resource-constrained country. Indian J Hematol Blood Transfus. 2022, 38:309-18. 10.1007\/s12288-021-01485-y","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1731599","article-title":"Hematopoietic stem cell transplant for hematological malignancies: experience from a tertiary care center in northern India and review of Indian data","volume":"11","author":"Sharma SK","year":"2022","unstructured":"Sharma SK, Choudhary D, Doval D, Khandelwal V, Setia R, Dadu T, Handoo A. Hematopoietic stem cell transplant for hematological malignancies: experience from a tertiary care center in northern India and review of Indian data. South Asian J Cancer. 2022, 11:62-7. 10.1055\/s-0041-1731599","journal-title":"South Asian J Cancer"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1748184","article-title":"Clinical outcomes of autologous hematopoietic stem cell transplant (HSCT) In multiple myeloma patients: 5-year experience from a single centre in north India","volume":"16","author":"Sood N","year":"2022","unstructured":"Sood N, Tiwari AK, Pabbi S, et al.. Clinical outcomes of autologous hematopoietic stem cell transplant (HSCT) In multiple myeloma patients: 5-year experience from a single centre in north India. South Asian J Cancer. 2022, 16:2022. 10.1055\/s-0042-1748184","journal-title":"South Asian J Cancer"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010055","article-title":"Allogeneic stem cell transplantation in multiple myeloma","volume":"14","author":"Greil C","year":"2021","unstructured":"Greil C, Engelhardt M, Finke J, W\u00e4sch R. Allogeneic stem cell transplantation in multiple myeloma. Cancers (Basel). 2021, 14:10.3390\/cancers14010055","journal-title":"Cancers (Basel)"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.138917","article-title":"Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT","volume":"101","author":"Paviglianiti A","year":"2016","unstructured":"Paviglianiti A, Xavier E, Ruggeri A, et al.. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. Haematologica. 2016, 101:1120-7. 10.3324\/haematol.2015.138917","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/141080-long-term-outcomes-of-autologous-hematopoietic-stem-cell-transplant-hsct-for-multiple-myeloma-while-new-horizons-emerge-it-is-still-only-a-silver-lining-for-resource-constrained-settings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:33Z","timestamp":1707508653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/141080-long-term-outcomes-of-autologous-hematopoietic-stem-cell-transplant-hsct-for-multiple-myeloma-while-new-horizons-emerge-it-is-still-only-a-silver-lining-for-resource-constrained-settings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":90,"URL":"https:\/\/doi.org\/10.7759\/cureus.36642","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}